menu
    • menu
    [{"orgOrder":0,"company":"Adamed Pharma","sponsor":"Adalvo","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"MALTA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Adamed Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Adamed Pharma \/ Adamed Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Adamed Pharma \/ Adamed Pharma"},{"orgOrder":0,"company":"Adamed Pharma","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus ATCC 53103","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adamed Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamed Pharma \/ Adamed Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Adamed Pharma \/ Adamed Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Adamed Pharma

    Menu

    Adamed Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adamed Pharma

                            Poland arrow
                            Pharmaconex
                            Not Confirmed

                            Adamed Pharma

                            Poland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Recipient : Adalvo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe

                            Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.

                            Product Name : Vesomni-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Recipient : Adalvo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adamed Pharma

                            Poland arrow
                            Pharmaconex
                            Not Confirmed

                            Adamed Pharma

                            Poland arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Rhamnosus ATCC 53103

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Medical University of Warsaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Childr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 20, 2020

                            Lead Product(s) : Lactobacillus Rhamnosus ATCC 53103

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Medical University of Warsaw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth